The inhibitory effect of Zingiber corallinum Hance essential oil on drug-resistant bacteria and evaluation of its acute toxicity

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Yang, Ce ^a   Zhou, Lin Lin ^a   Wang, Hai Yan ^a   Huang, Su Na ^a   Liu, Qing ^a   Hu, Shi Lin ^b   Li, Ting Rong ^b   Chen, Yan Bing ^b   Jiang, Jian Xin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Research Institute of Daily used Chemical Industry   (China)

Author keywords

Drug resistant bacteria; Terpinen 4 ol; Zingiber corallinum Hance essential oil

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CARBAPENEM; CEFOTAXIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ESSENTIAL OIL; GENTAMICIN; LEVOFLOXACIN; NITROFURANTOIN; PENICILLIN G; PIPERACILLIN; PLANT EXTRACT; SULBACTAM; TERPINEN 4 OL; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ZINGIBER CORALLINUM EXTRACT;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; GINGER; LETHAL DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ZINGIBER CORALLINUM;

EID: 79955933204     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881760     Document Type: Article

References (54)

1. Davis KA, Stewart JJ, Crouch HK et al: Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis, 2004; 39: 776-82
2. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, Paul-Ehrlich-Society for Chemotherapy: Paul-Ehrlich-Society for Chemotherapy: Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int J Antimicrob Agents, 2004; 23: 577-81
3. Hammer KA, Carson CF, Riley TV: Influence of organic matter, cations and surfactants on the antimicrobial activity of Melaleuca alternifolia (tea tree) oil in vitro. J Appl Microbiol, 1999; 86: 446-52
4. Edris AE: Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res, 2007; 21: 308-23
5. Zhang RY, Yu DS: Research and progress in traditional plant Zingiber Corallinum Hance. Journal of Sichuan of Traditional Chinese Medicine, 2004; 22: 26-28
6. Cao Y, Zhang SY, Zhu RH: Investigation of anti-fungal effects by wild plant Zingiber Corallinum Hance and its Clinical therapeutic effect. Chin J Derm Venereol, 1989; 22: 103-5
7. Nishio H, Komatsu M, Shibata N et al: Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J Clin Microbiol, 2004; 42: 5256-63
8. Chen NN, Cao Y, Li SF: Research on the antibacterial effects of Zingiber Corallinum Hance. Oil and tea tree oil on five type of bacteria. Health professional education, 2007; 25: 102-3
9. Cao Y, Zhang SY, Zhu RH: Ultrastructure Observation of T. Tubrum Affected by 1% Essential 0lium of Zingiber Corallinum Hance with TEM. Journal of Guiyang Medical College, 1990; 15: 58-60
10. Yang ZN, Luo SQ, Peng QC et al: GC-MS Analysis of the Essential Oil of Coral Ginger (Zingiber corallinum Hance) Rrhizome Obtained by Supercritical Fluid Extraction and Steam Distillation Extraction. Chromatographia, 2009; 69: 785-90
11. Jiang YP, Cao Y, Li SF: Experimental studies on the inhibitory effects of Zingiber Corallinum Hance essential elements on pityrosporion ovale. Journal of Guiyang Chinese Medical College, 2006; 5: 57-59
12. Dent LL, Marshall DR, Pratap S, Hulette RB: Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis, 2010; 10: 196
13. Hamouda A, Vali L, Amyes SG: Gram-negative non-fermenting bacteria from food-producing animals are low risk for hospital-acquired infections. J Chemother, 2008; 20: 702-8
14. Choi WS, Kim SH, Jeon EG, Son MH, Yoon YK, Kim JY, et al: Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J Korean Med Sci, 2010; 25: 999-1004
15. Garnacho-Montero J, Amaya-Villar R: Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010; 23: 332-39
16. Ozbek B, Otük G: In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units. Int J Antimicrob Agents, 2010; 36(2): 191-92
17. Higgins PG, Dammhayn C, Hackel M, Seifert H: Global spread of carbapenem- resistant Acinetobacter baumannii. J Antimicrob Chemother, 2010; 65: 233-38
18. Merkier AK, Catalano M, Ramírez MS et al: Polyclonal spread of bla(OXA-23) and bla(OXA-58) in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries, 2008; 2: 235-40
19. Martins AF, Kuchenbecker R, Sukiennik T et al: Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme: dissemination in Southern Brazil. Infection, 2009; 37: 474-76
20. Doi Y, Wachino J, Yamane K et al: Spread of novel aminoglycoside resistance gene aac(6')-Iad among Acinetobacter clinical isolates in Japan. Antimicrob Agents Chemother, 2004; 48: 2075-80
21. Ho PL, Ho AY, Chow KH et al: Epidemiology and clonality of multidrug- resistant Acinetobacter baumannii from a healthcare region in Hong Kong. J Hosp Infect, 2010; 74: 358-64
22. Jeoung OY, Jang SJ, Li XM et al: Prevalence and spread of integron-IS26 in imipenem-resistant Acinetobacter baumannii clinical isolates in South Korea. Int J Antimicrob Agents, 2009; 34: 612-14
23. Sneath PHA, NS Mair, ME Sharpe, JG Holt: Bergey's Manual of Systematic Bacteriology (9th edn.). Vol. 2. The Williams and Wilkins Co., Baltimore, MD, 1986
24. Williams ST, ME Sharpe, JG Holt: Bergey's Manual of Systematic Bacteriology (9th edn.). Vol. 4. The Williams and Wilkins Co., Baltimore, MD, 1989
25. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - 6th Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003
26. Armitage P, Allen I: Methods of estimating the LD 50 in quantal response data. J Hyg (Lond), 1950; 48: 298-322
27. Barnard DL, Wong MH, Bailey K et al: Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antivir Chem Chemother, 2007; 18: 125-32
28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005
29. Joseph NM, Sistla S, Dutta TK et al: Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. J Infect Dev Ctries, 2010; 4: 218-25
30. Al Kandari M, Jamal W, Udo EEEl Sayed A et al: A case of communityonset meningitis caused by hospital methicillin-resistant Staphylococcus aureus successfully treated with linezolid and rifampicin. Med Princ Pract, 2010; 19: 235-39
31. Markogiannakis H, Pachylaki N, Samara E et al: Infections in a surgical intensive care unit of a university hospital in Greece. Int J Infect Dis, 2009; 13: 145-53
32. Lazarus HM, Fox J, Lloyd JF et al: A six-year descriptive study of hospital- associated infection in trauma patients: demographics, injury features, and infection patterns. Surg Infect (Larchmt), 2007; 8: 463-73
33. Cao Y, Cheng B, Wu CL: Culture and Analysis of An tibacterial Activity of Staphylococcus Aureus on the Skin Sarface of Atopic Dermatitis. Chin J Derm Venereol, 2005; 19: 474-75
34. Cheng B, Xie G, Yao S et al: Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med, 2007; 35: 2538-46
35. Xu SY: Miao ethnic medicines: application, research and development. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica, 2006; 8: 73-78
36. Hammer KA, Carson CF, Riley TV: In vitro activity of Melaleuca alternifolia (tea tree) oil against dermatophytes and other filamentous fungi. J Antimicrob Chemother, 2002; 50: 195-99
37. Jiang XM, Shi QD: Structural characterization of the pachymaran and the carboxymethyl-pachymaran. Journal of Guangxi Normal University, 1996; 14: 40-46
38. Houang ET, Chu YW, Leung CM et al: Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol, 2001; 39: 228-34
39. Lee K, Ha GY, Shin BM et al: Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) group. Metallo-beta-lactamaseproducing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis, 2004; 50: 51-58
40. Levin AS, Mendes CM, Sinto SI et al: An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol, 1996; 17: 366-68
41. Liu SY, Lin JY, Chu C et al: Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents, 2006; 27: 81-84
42. Naas T, Levy M, Hirschauer C et al: Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol, 2005; 43: 4826-29
43. Quale J, Bratu S, Landman D, Heddurshetti R: Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis, 2003; 37: 214-20
44. Van Looveren M, Goossens H; ARPAC Steering Group: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect, 2004; 10: 684-704
45. Rahal JJ, Urban C: Acinetobacter. Semin Respir Crit Care Med, 2000; 21: 341-48
46. Calhoun JH, Murray CK, Manring MM: Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res, 2008; 466: 1356-62
47. Stuart TL, Mulvey M, Simor AE et al: Acinetobacter baumannii in casualties returning from Afghanistan. Can J Infect Control, 2007; 22: 152-54
48. Centers for Disease Control and Prevention (CDC): Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep, 2004; 53: 1063-66
49. May J, Chan CH, King A et al: Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother, 2000; 45: 639-43
50. Burt S: Essential oils: their antibacterial properties and potential applications in foods - a review. Int J Food Microbiol, 2004; 94: 223-53
51. Wendakoon CN, Sakaguchi M: Inhibition of amino acid decarboxylase activity of Enterobacter aerogenes by active components in spices. J Food Prot, 1995; 58: 280-83
52. Nicolson K, Evans G, O'Toole PW: Potentiation of methicillin activity against methicillin-resistant Staphylococcus aureus by diterpenes. FEMS Microbiol Lett, 1999; 179: 233-39
53. Osborn TM, Tracy JK, Dunne JR et al: LEpidemiology of sepsis in patients with traumatic injury. Crit Care Med, 2004; 32: 2234-40
54. Carson F, Hammer A, Riley V: Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev, 2006; 19: 50-62.